Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327223 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
A Phase 1 study, sponsored by AmpliMed Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00327223 is a Phase 1 study that has completed, run by AmpliMed Corporation. The registered enrollment target is 18 participants.
The verdict
NCT00327223, a Phase 1 study, has completed, sponsored by AmpliMed Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.
Interventions
- DRUG imexon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00327223
The ClinicalTrials.gov registry entry for NCT00327223 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AmpliMed Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which imexon is the first listed.
NCT00327223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00327223 about?
NCT00327223 is a clinical study titled "Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy". AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of t...
What is the current status of trial NCT00327223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2005-11. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00327223?
The interventions under investigation include: imexon (DRUG).
Who is sponsoring clinical trial NCT00327223?
This trial is sponsored by AmpliMed Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.